Today, a Director at Sangamo Biosciences (NASDAQ: SGMO), Stewart Parker, bought shares of SGMO for $27.04K.
This recent transaction increases Stewart Parker’s holding in the company by 57.14% to a total of $71.78K. This is Parker’s first transaction since reporting a Buy transaction on ACHV back in May 2013
See today’s analyst top recommended stocks >>
Based on Sangamo Biosciences’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $21.42 million and GAAP net loss of $16.64 million. In comparison, last year the company earned revenue of $8.25 million and had a GAAP net loss of $12.49 million. Currently, Sangamo Biosciences has an average volume of 3.11M.
Based on 3 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $19.00, reflecting a 38.2% upside.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sangamo Therapeutics, Inc. researches and develops transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. The company was founded by Edward O. Lanphier II on June 22, 1995 and is headquartered in Richmond, CA.
Read More on SGMO:
